Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
James Januzzi, MD
PeerMartin Maron, MD
PeerMarianna Fontana, MD
PeerLong-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
Alexander Fanaroff, MD
PeerHadley Wilson, MD
PeerAngiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
Akshay S. Desai, MD
PeerMarc Bonaca, MD
PeerPromising results for APOC3 ASO in familial chylomicronemia syndrome
Erik Stroes, MD, PhD
PeerIncreasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Alexander J. Blood, MD
PeerSteven Nissen, MD
PeerMore than 70% lowering of triglycerides with APOC3 RNAi in patients with severe hypertriglyceridemia
Daniel Gaudet, MD, PhD
PeerSemaglutide Reduces CV Events in Non-Diabetic, Overweight Patients
Stopping aspirin after 1 month DAPT in ACS patients after stenting
Gregg Stone, MD
PeerHead-to-head comparison of two TAVR devices in patients with aortic stenosis and small aortic annuli
Howard C. Herrmann, MD
PeerAPOC3 ASO significantly lowers triglycerides in patients with hypertriglyceridemia and high CV risk
Brian Bergmark, MD
Peer